An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. (2022)

First Author: Lin J

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fimmu.2022.1022598

PubMed Identifier: 36505399

Publication URI: http://europepmc.org/abstract/MED/36505399

Type: Journal Article/Review

Volume: 13

Parent Publication: Frontiers in immunology

ISSN: 1664-3224